Track topics on Twitter Track topics that are important to you
NICE has chalked up a new first in its assessment of treatments for use on the NHS, ruling that the health service should fund GlaxoSmithKline’s gene therapy Strimvelis for the treatment of adenosine deaminase deficiency (ADA-SCID) – also known as ‘bubble baby syndrome’ – marking the first time the body has recommended a treatment which is currently only available in another country.NEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...